Form 4: Verve Therapeutics CSO Reports Full Equity Disposition Following Eli Lilly Acquisition

Verve Therapeutics' Chief Scientific Officer, Troy Lister, reported the complete disposition of his beneficial ownership in company stock and equity awards as a result of the company's acquisition by Eli Lilly and Company, effective July 25, 2025.

Summary

• Verve Therapeutics, Inc. was acquired by Eli Lilly and Company through its indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, with the merger becoming effective on July 25, 2025.
• The acquisition involved a tender offer where tendering stockholders received $10.50 per share in cash (Cash Consideration) plus one non-tradable Contingent Value Right (CVR).
• Each CVR represents a contractual right to receive a contingent payment of up to $3.00 per CVR upon the achievement of a specified business milestone.
• Troy Lister, Chief Scientific Officer, disposed of 6,952 shares of common stock as part of the merger.
• Outstanding stock options with an exercise price less than the Cash Consideration (e.g., 225,000 options at $6.01 and 32,000 options at $5.29) were cancelled, with holders receiving cash equal to the difference between the Cash Consideration and the exercise price, multiplied by the number of shares, plus one CVR per share.
• Unvested Restricted Stock Units (RSUs), including 40,000, 12,075, and 6,630 units, were cancelled, with holders receiving cash equal to the Cash Consideration multiplied by the number of units, plus one CVR per unit.
• Stock options with an exercise price equal to or greater than the Cash Consideration but less than the sum of the Cash Consideration and the Milestone Payment (e.g., 69,500 options at $12.75) were cancelled, with holders entitled to receive a cash payment equal to the CVR payment, provided the total value (Cash Consideration + Milestone Payment) exceeds the exercise price.
• Following these transactions, Troy Lister holds 0 shares and 0 derivative securities in Verve Therapeutics.

Sentiment

Score: 7

Explanation: The filing indicates the successful completion of a merger, providing liquidity to shareholders and equity holders. The inclusion of a CVR offers potential additional upside, though contingent. For the reporting person, it signifies the conversion of their equity into cash and CVRs as per the merger terms.

Positives

• The merger provides a clear exit strategy and immediate liquidity for Verve Therapeutics shareholders and equity award holders.
• Equity award holders received a combination of cash and Contingent Value Rights (CVRs), offering potential additional upside if the specified milestone is achieved.

Negatives

• Verve Therapeutics ceased to be an independent publicly traded entity, removing direct investment opportunities in the company's stock.
• The full value of the Contingent Value Right (CVR) is contingent on a future milestone, introducing uncertainty regarding the total consideration received.

Risks

• The contingent payment of up to $3.00 per CVR is dependent on the achievement of a specific business milestone, meaning the full potential value may not be realized if the milestone is not met.

Future Outlook

The filing details the completed acquisition of Verve Therapeutics by Eli Lilly and Company, resulting in Verve becoming a wholly owned subsidiary. Future financial performance and strategic direction will be integrated within Eli Lilly's operations, with a contingent payment tied to a specific milestone for former Verve shareholders and equity holders.

Industry Context

This acquisition reflects the ongoing consolidation trend within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire innovative smaller biotechs to expand their pipelines and intellectual property. The use of Contingent Value Rights (CVRs) is a common mechanism in such deals to bridge valuation gaps and incentivize the achievement of specific development or regulatory milestones post-acquisition.

Comparison to Industry Standards

• The use of a cash-plus-CVR structure is a standard practice in biotech mergers and acquisitions, particularly for companies with promising but unproven assets.
• Similar structures have been observed in other significant biotech deals, such as Bristol Myers Squibb's acquisition of MyoKardia or Sanofi's acquisition of Principia Biopharma, where CVRs were tied to regulatory approvals or sales milestones.
• The specific cash consideration of $10.50 per share and a potential $3.00 CVR should be evaluated against Verve's pre-announcement trading price and analyst price targets to assess the premium offered, although this filing does not provide that comparative context.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, providing liquidity and potential future upside.
• Employees (holding equity awards): Their stock options and RSUs were converted into cash and CVRs, similar to shareholders, providing immediate value and contingent future payments.
• Company (Verve Therapeutics): Ceased to be an independent public entity, becoming a wholly owned subsidiary of Eli Lilly, impacting its strategic autonomy and operational structure.

Next Steps

• Achievement and verification of the specified milestone for the Contingent Value Right (CVR) payment.
• Integration of Verve Therapeutics' operations and assets into Eli Lilly and Company.

Key Dates

Keywords

Verve Therapeutics, Eli Lilly, Merger, Acquisition, Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Stock Units, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals